Published in J Cell Biochem Suppl on January 01, 1995
A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila) (2009) 1.51
Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther (2009) 1.31
Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem (1997) 1.25
Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer (2004) 1.24
Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) (2011) 1.13
A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prev Res (Phila) (2012) 1.11
Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther (2013) 1.10
Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08
Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene (2012) 1.04
Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis (2002) 1.01
Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) (2010) 1.00
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res (2013) 0.96
New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res (2013) 0.83
Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol (2015) 0.83
Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. Oncotarget (2015) 0.78
NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals (Basel) (2010) 0.78
Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases. Curr Colorectal Cancer Rep (2012) 0.77
Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems. Oncol Discov (2013) 0.77
Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. Curr Pharmacol Rep (2015) 0.75
Phosphodiesterases in non-neoplastic appearing colonic mucosa from patients with colorectal neoplasia. BMC Cancer (2016) 0.75
Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA (2001) 8.40
Colorectal cancer prevention 2000: screening recommendations of the American College of Gastroenterology. American College of Gastroenterology. Am J Gastroenterol (2000) 4.17
Validity of self-reported colorectal cancer screening behavior. Cancer Epidemiol Biomarkers Prev (2000) 3.07
Common inheritance of susceptibility to colonic adenomatous polyps and associated colorectal cancers. N Engl J Med (1988) 3.01
Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther (2000) 2.96
Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology (1997) 2.96
A simple, versatile, nondisruptive method for the isolation of morphologically and chemically pure basement membranes from several tissues. Life Sci (1975) 2.10
Familial colorectal cancer risk by subsite of primary cancer: a population-based study in Utah. Aliment Pharmacol Ther (2015) 2.03
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res (1997) 2.00
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res (2000) 2.00
Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology (1993) 1.97
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res (1995) 1.94
Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. Nat Genet (1998) 1.71
Dominant inheritance of adenomatous colonic polyps and colorectal cancer. N Engl J Med (1985) 1.58
Colonic polyps in an unselected population: prevalence, characteristics, and associations. Am J Gastroenterol (1994) 1.53
Process of care and outcomes for elderly patients hospitalized with peptic ulcer disease: results from a quality improvement project. JAMA (2001) 1.51
Hypoglycin and hypoglycin-like compounds. Pharmacol Rev (1969) 1.41
Studies of the mechanism of the hypoglycemic action of 4-pentenoic acid. Proc Natl Acad Sci U S A (1967) 1.40
Minimal biotransformation and toxicity of desflurane in guinea pig liver slices. Anesth Analg (1991) 1.39
Quantitation of colonic injury from argon laser, neodymium: YAG laser and monopolar electrocautery applied to flat mucosa and small sessile polyps of the canine colon. Gastrointest Endosc (1989) 1.39
Benign recurrent intrahepatic cholestasis: treatment with S-adenosylmethionine. Gastroenterology (1989) 1.39
Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol (1994) 1.39
The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. Br J Surg (1980) 1.38
Ion-exchange separation and automated assay of complex mixtures of amino acids and hexosamines. Anal Biochem (1970) 1.36
Classification and risk assessment of individuals with familial polyposis, Gardner's syndrome, and familial non-polyposis colon cancer from [3H]thymidine labeling patterns in colonic epithelial cells. Cancer Res (1984) 1.35
pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose. J Immunol Methods (1979) 1.31
Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther (2001) 1.30
Upper gastrointestinal polyps in Gardner's syndrome. Gastroenterology (1984) 1.30
Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res (2001) 1.29
Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res (1997) 1.28
Precision-cut tissue slices: applications in pharmacology and toxicology. Life Sci (1995) 1.27
Measurement of chemopreventive efficacy in skin biopsies. Anal Quant Cytol Histol (2001) 1.25
The in vitro inhibition of insulin secretion by diphenylhydantoin. J Clin Invest (1970) 1.24
Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst (1994) 1.23
The role of carnitine and carnitine acyltransferase in biological acetylations and fatty acid synthesis. J Biol Chem (1966) 1.21
A K-ras oncogene increases resistance to sulindac-induced apoptosis in rat enterocytes. Gastroenterology (1997) 1.18
Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol (1999) 1.18
Isolated brain microvessels: a purified, metabolically active preparation from bovine cerebral cortex. Science (1974) 1.16
The polyp prevention trial I: rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev (1996) 1.15
Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res (1999) 1.12
Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res (2000) 1.11
Ultrastructural and biochemical analyses of isolated basement membranes from kidney glomeruli and tubules and brain and retinal microvessels. J Ultrastruct Res (1978) 1.11
Evaluation of complicating osteomyelitis with Tc-99m MDP, In-111 granulocytes, and Ga-67 citrate. J Nucl Med (1984) 1.09
Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology (1999) 1.08
Constitutional mismatch repair-deficiency syndrome presenting as colonic adenomatous polyposis: clues from the skin. Clin Genet (2010) 1.08
Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol (1989) 1.08
Brain scan abnormalities produced by electroencephalographic procedures. J Nucl Med (1974) 1.07
Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst (1999) 1.05
Human diabetic perineurial cell basement membrane thickening. Lab Invest (1981) 1.03
Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev (1994) 1.03
Prevention of colorectal cancer: guidelines based on new data. WHO Collaborating Center for the Prevention of Colorectal Cancer. Bull World Health Organ (1995) 1.03
Expression in normal human tissues of five nucleotide excision repair genes measured simultaneously by multiplex reverse transcription-polymerase chain reaction. Cancer Epidemiol Biomarkers Prev (1999) 1.02
The histopathology of fundic gland polyps of the stomach. Am J Clin Pathol (1986) 1.02
Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. Gastroenterology (2001) 1.00
Characteristics of familial colon cancer in a large population data base. Cancer (1989) 0.98
Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey. Br J Clin Pharmacol (2007) 0.98
Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut (2005) 0.98
Thickened cerebral cortical capillary basement membranes in diabetics. Arch Pathol Lab Med (1982) 0.97
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol (1999) 0.97
The effect of 4-pentenoic acid on fatty acid oxidation. Biochem Biophys Res Commun (1969) 0.97
Regional cardiac sympathetic denervation in patients with ventricular tachycardia in the absence of coronary artery disease. J Am Coll Cardiol (1993) 0.96
Cisplatin nephrotoxicity: in vitro studies with precision-cut rabbit renal cortical slices. Toxicol Appl Pharmacol (1987) 0.96
Improved methods for harvesting and counting synchronous populations of Artemia nauplii for use in developmental toxicology. Ecotoxicol Environ Saf (1983) 0.94
The resolution of (plus or minus)-carnitine and the synthesis of acylcarnitines. Biochim Biophys Acta (1967) 0.94
Villous adenoma of the duodenal papilla presenting as necrotizing pancreatitis in a patient with Gardner's syndrome. Gastroenterology (1987) 0.93
AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis (1997) 0.93
Preparation and composition of alveolar extracellular matrix and incorporated basement membrane. Lung (1981) 0.93
Properties of a pure metabolically active glomerular preparation from rat kidneys. I. Isolation. J Pharmacol Exp Ther (1973) 0.93
Effects of 4-pentenoic acid on carbohydrate metabolism in pigeon liver homogenate. J Biol Chem (1969) 0.93
Dihydrocapsaicin-induced hypothermia and substance P depletion. Eur J Pharmacol (1982) 0.92
High prevalence of adenomatous polyps of the duodenal papilla in familial adenomatous polyposis. Dig Dis Sci (1989) 0.91
Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat (1998) 0.91
Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst (1995) 0.91
Detergent-extracted small-diameter vascular prostheses. J Vasc Surg (1984) 0.91
Detection of mammary micrometastases by pregnancy-associated alpha 2-glycoprotein (PAG, alpha 2-PAG or PAM) and carcinoembryonic antigen (CEA). Eur J Cancer (1979) 0.90
In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol (1982) 0.90
Congenital hypertrophy of the retinal pigment epithelium predicts colorectal polyposis in Gardner's syndrome. Arch Ophthalmol (1990) 0.90
Effect of hypoxemia on sodium and water excretion in chronic obstructive lung disease. Am J Med (1985) 0.89
Ultrastructural analyses of control and enzyme-treated isolated renal basement membranes. Anat Rec (1981) 0.89
Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Scand J Gastroenterol Suppl (1992) 0.89
Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol Biomarkers Prev (1995) 0.89
Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis (1998) 0.89
Serrated adenomatous polyposis: a new syndrome? Gastroenterology (1996) 0.89